Three-year outcomes following TAVR in younger (<75 years) low-surgical-risk severe aortic stenosis patients
Recommended Citation
Modine T, Tchétché D, Van Mieghem NM, et al. Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients. Circ Cardiovasc Interv. 2024;17(11):e014018. doi:10.1161/CIRCINTERVENTIONS.124.014018
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged
Methods: The Evolut Low Risk Trial randomized 1414 low-risk patients to treatment with a supra-annular, self-expanding TAVR or surgery. We compared rates of all-cause mortality or disabling stroke, associated clinical outcomes, and bioprosthetic valve performance at 3 years between TAVR and surgery patients aged
Results: In patients P=0.241). Although there was no difference between TAVR and surgery in all-cause mortality, the incidence of disabling stroke was lower with TAVR (0.6%) than surgery (2.9%; P=0.019), while surgery was associated with a lower incidence of pacemaker implantation (7.1%) compared with TAVR (21.0%; PP=0.962) were low in both groups. Valve performance was significantly better with TAVR than surgery with lower mean aortic gradients (PP
Conclusions: Low-risk patients
Type
Article
PubMed ID
39421943
Affiliations
Aurora St. Luke's Medical Center